This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Detection of TMPRSS2:ERG fusion gene in circulating prostate
cancer cells
Xueying Mao1, Greg
Shaw1,2, Sharon Y. James1, Patricia
Purkis1, Sakunthala C.
Kudahetti1, Theodora
Tsigani1, Saname Kia1, Bryan D.
Young1, R. Tim D. Oliver1, Dan
Berney3, David M. Prowse2, Yong-Jie
Lu1
1Medical Oncology and
2Molecular Oncology Centres, Institute of Cancer,
3Department of Histopathology and Morbid
Anatomy, Barts and London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square,
London EC1M 6BQ, UK
Abstract
Aim: To investigate the existence of TMPRSS2:ERG
fusion gene in circulating tumor cells (CTC) from prostate
cancer patients and its potential in monitoring tumor
metastasis. Methods: We analyzed the frequency of
TMPRSS2:ERG and TMPRSS2:ETV1 transcripts in 27 prostate cancer biopsies from prostatectomies, and
TMPRSS2:ERG transcripts in CTC isolated from 15 patients with advanced androgen independent disease using reverse transcription
polymerase chain reaction (RT-PCR). Fluorescence
in situ hybridization (FISH) was applied to analyze the genomic
truncation of ERG, which is the result of
TMPRSS2:ERG fusion in 10 of the 15 CTC samples.
Results: TMPRSS2:ERG transcripts were found in 44% of our samples, but we did not detect expression
of TMPRSS2:ETV1. Using FISH analysis we detected chromosomal rearrangements affecting
the ERG gene in 6 of 10 CTC samples, including
1 case with associated TMPRSS2:ERG fusion at the primary site. However,
TMPRSS2:ERG transcripts were not detected in any of the 15 CTC samples, including the 10 cases analyzed by FISH.
Conclusion: Although further study is required to address the association between
TMPRSS2:ERG fusion and prostate cancer metastasis, detection
of genomic truncation of the ERG gene by FISH analysis could be useful for monitoring the appearance of CTC and
the potential for prostate cancer metastasis. (Asian J Androl 2008 May; 10: 467_473)
Keywords: TMPRSS2:ERG; fusion gene; prostate cancer; metastasis; circulating tumor cells; fluorescence
in situ hybridization; polymerase chain reaction
Correspondence to: Dr Yong-Jie Lu, Medical Oncology Centre, Cancer Institute, Barts and London School of Medicine and Dentistry,
Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK.
Tel: +44-20-7882-6140 Fax: +44-20-7882-6004
E-mail: yong.lu@cancer.org.uk
Received 2007-11-09 Accepted 2008-02-20
DOI: 10.1111/j.1745-7262.2008.00401.x
1 Introduction
Prostate cancer is the most common non-cutaneous malignancy in men living in developed nations [1]. Most
prostate cancers diagnosed at an early stage are latent, but once having progressed they become life threatening, and,
despite recent advances, late stage prostate cancer is still incurable [2]. With the general application of prostate
specific antigen (PSA) testing for prostate cancer screening and diagnosis, there is also a dilemma in the clinical
treatment of early stage cancers, because it is difficult to predict their progression potential [2]. Current methods
either over-treat the majority of early prostate cancer patients who will not die from prostate cancer even without
treatment, or miss the opportunity to cure early stage aggressive disease. As it is the metastatic and androgen
independent disease that is responsible for cancer deaths, detecting signs of aggressive cancer in clinically early stages
of the disease would be invaluable [3, 4]. However, there are currently no reliable prognostic biomarkers to predict
prostate cancer progression and metastastic potential [2,
4].
Fusion genes have been studied a great deal in
hematological malignancies and soft tissue sarcomas, where
they frequently define a tumor subtype and are
associated with prognosis. The recurrent fusion of
the TMPRSS2 and ETS family transcription factor genes was
recently identified in prostate cancer [5, 6]. Fusion genes
are de novo genes generated in cancer cells. They can
be used as a marker to detect cancer cells in minimum
residual disease [7], and also as targets for cancer cell
specific treatment [5, 8]. If these fusion genes,
particularly the high frequency of TMPRSS2:ERG
fusion gene, play a role in tumor progression and, most importantly,
tumor metastasis, they will be invaluable markers for
treatment stratification and targets for novel forms of
therapy. However, studies on the association between
TMPRSS2:ETS fusion gene and tumor progression have
generated inconsistent results, and few studies have
attempted to address the role of the fusion gene in
advanced metastastic prostate cancer [9_17].
Long distance tumor metastasis is caused by tumor
cell migration from the primary site into the blood stream,
culminating in survival and re-establishment at a new site.
It has been known for 150 years that tumor cells are
detectable in the blood of patients with advanced cancer
[18]. Sampling circulating tumor cells (CTC) may be
used to study genetic and gene expression alterations in
a continual, relatively non-invasive fashion, and to
monitor treatment. Using genetic and/or biomarkers to detect
the CTC might also provide informed treatment planning.
With the recent advances in use of specific antibodies
and various sorting techniques following antibody labeling,
the ratio of epithelial to blood cells can be augmented so
that analysis of these cells is more feasible [19_21].
However, many genes associated with prostate
carcinogenesis are also expressed in hematopoietic cells, and
the existence of non-tumor epithelial cells in the
peripheral blood complicates CTC analysis [22, 23]. For
prostate cancer, the detection of micrometastases is also
limited by the lack of specific cancer cell markers [22,
24, 25]. As the TMPRSS2:ERG fusion gene occurs at a
high frequency in prostate cancer and is a specific
genetic marker of abnormal prostate cells, we have attempted
to detect its existence in CTC to monitor tumor
progression and metastatic potential.
2 Materials and methods
2.1 Materials
Twenty-seven primary prostate cancer biopsies from
radical prostatectomy and fifteen peripheral blood samples
from patients with advanced prostate cancer (with
metastasis or PSA > 40 ng/mL) were obtained from local
hospitals with patients' consent and local research
ethical committee's approval. A cancer biopsy and a blood
sample were available from 1 patient (primary biopsy
PC127 and blood sample PCB34). The
clinico-pathological data are summarized in Tables 1 and 2. All blood
samples were taken from patients who received second
line hormone therapy, except for PCB32, who was on
first line treatment. Tissue biopsies were kept snap
frozen in liquid nitrogen and all samples in the present study
were confirmed with cancer by a consultant
histopathologist (Dan Berney), who reviewed fresh frozen sections
from the collected tissue.
2.2 Cell separation and circulating tumor cells
purification from blood samples
Peripheral blood samples were collected in
EDTA-coated tubes and processed as follows. From a small
volume (5 mL) blood collection, lymphocytes and
tumor cells were separated from red cells by spinning in
Ficoll gradient buffer and then used directly for RNA
extraction. From a large volume (20 mL) blood
collection, CTC were purified by magnetic cell sorting. Initially,
the red blood cells and the majority of the white blood
cells were removed from the 20 mL blood sample by
spinning in an Oncoquick tube pre-filled with separation
buffer (Greiner; Kremsmuenster, Austria). The aspirate
was then washed twice with Oncoquick washing buffer
and resuspended in MACS running buffer (Miltenyi Biotech; Surrey, UK) for CTC selection. A negative
selection for cells which were labeled with CD45 (a
lymphocyte marker) was performed using AutoMACS (Miltenyi Biotech). This was followed by a positive
selection for cells labeled with EpCAM (Epithelial Cell
Adhesion Molecule) microbeads.
2.3 Immunostaining
EpCam (Abcam, Cambridge, UK) antibodies were used
at concentrations recommended by the manufacturers.
CTC were air dried onto slides, fixed, incubated
overnight with primary antibodies and detected using
appropriate secondary antibodies. Nuclear counterstaining was
performed using 4,6-diamidino-2-phenylindole dihydrochloride (DAPI). Stained preparations were
analyzed on a Zeiss 510 confocal microscope (Carl Zeiss
Ltd.; Jena, Germany).
2.4 RNA extraction and reverse transcription polymerase
chain reaction (RT-PCR) analysis
RNA was extracted from snap frozen tissues and Ficoll separated cells from the small blood volume
samples using the Trizol method following the
manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The
RNeasy Mini kit (Qiagen, Crawley, UK) was also used
according to the manufacturer's instructions to extract
RNA from the CTC.
Reverse transcription of RNA was performed using
the Superscript II enzyme (Invitrogen). Random
primers (6pN) were used for RNA extracted from the cancer
biopsies and the Poly-A primer was used for RNA from
the circulating cells.
The primers (for TMPRSS2:ERG forward primer
CAGGAGGCGGAGGCGGA and reverse primer GGCGTTGTAGCTGGGGGTGAG and for
TMPRSS2:ETV1 forward primer CAGGAGGCGGAGGCGGA and
reverse primer TTGTGGTGGGAAGGGGATGTTT) described by
Tomlins et al. [5, 8] were used for PCR
amplification with an annealing temperature of 65ºC. For
standard RT-PCR, 35 cycles were used, and 40 cycles
were used for quantitative RT-PCR (Q-RT-PCR).
β-actin with the forward primer gatgagatt
ggcatggcttt and reverse primer caccttcac
cgttccagttt was used as a positive control. The Opticon DNA
Engine 2 (MJ Research, Waltham, USA) was used to
perform the Q-RT-PCR thermal cycling and Opticon
monitor software (MJ Research) was used for data analysis.
2.5 Sequence analysis
PCR products were cloned into the pCR 2.1-TOPO Vector using the TOPO TA Cloning Kit (Invitrogen).
Single bacterial clones were picked and directly lysed in
PCR buffer for insert amplification using the M13F and
M13R primers and then sequenced using the ABI Prism
3700 DNA Analyser (Applied Biosystem). DNA sequences
were analyzed using the 4 Peaks software (Netherlands
Cancer Institute, Amsterdam, the Netherlands).
2.6 Fluorescence in situ hybridization
The BAC clones (RP11-95I21 and RP11-476D17) on either side of
the ERG gene were obtained from The Sanger Institute (Cambridge, UK) and differentially
labeled in red and green fluorescent dyes, as previously
described [26]. CTC cells were dropped onto glass slides
and fixed in situ with ethanol. Before hybridization, they
were pretreated in 70% acetic acid for 10 min to remove
the cytoplasm. Then slides and probes were denatured
separately and hybridized overnight at 37ºC following
standard fluorescence in situ hybridization (FISH)
methodology. Hybridized cells were counterstained by DAPI and
images were captured using an Olympus fluorescence
microscope (Olympus Optical Co. Ltd., Tokyo, Japan)
mounted with a cooled coupled device camera controlled
by the computer software Mac Probe 4.3 (Applied Imaging, Newcastle, UK).
2.7 Statistics
The Fisher exact test was performed to compare the
frequency of TMPRSS2:ERG fusion gene between the
primary sample and the CTC.
3 Results
We analyzed 27 primary prostate cancer biopsies
from radical prostatectomy using standard RT-PCR for
both the TMPRSS2:ERG and TMPRSS2:ETV1
fusion genes. Of the samples, 12 (44%)
were TMPRSS2:ERG fusion positive and in 7 samples more than one form of
fusion transcripts were detected (Table 1). The most
common fusion form detected in 9 of the 12 positive
cases was between exon 1 of TMPRSS2 and exon 4
of ERG (T1/E4), as originally reported by Tomlins
et al. [5, 8]. Other fusion forms, such as T1/E2, T1/E5 and
T2/E5, as previously reported by Clark
et al. [14, 27_30], were also detected. The
TMPRSS2:ETV1 fusion gene was not detected in any samples.
As the TMPRSS2:ERG fusion gene occurred at a
very high frequency, we further investigated the
possibility of detecting its fusion transcripts by blood testing.
We analyzed four peripheral blood samples (one of them,
PCB34, taken from a fusion positive case, PC127) using
standard RT-PCR. We took 5 mL of blood from each
sample, and failed to detect any fusion products.
Because both lack of CTC in the small blood volume
and a large amount of lymphocyte contamination could
result in the failure to detect the fusion gene, we further
analyzed the separated CTC from 20 mL blood samples
from patients with advanced androgen independent
prostate cancer receiving second line hormone therapy. The
purity of cancer cells was enriched and each sample
contained more than 100 nucleated CD45 negative,
cytokeratin/EpCAM positive cells (Figure 1).
However, of the 15 samples analyzed using both standard RT-PCR and
Q-RT-PCR, including 1 case in which the primary cancer
biopsy was fusion positive, no fusion transcripts were
detected in any CTC (Figure 2A, B). We confirmed the
sensitivity of our RT-PCR protocol in detecting
TMPRSS2:ERG fusion transcripts by mixing different dilutions of
fusion positive VCaP cells with fusion negative LNCaP
cells. We detected the fusion product in approximately
20 (100 pg RNA) but not 10 (50 pg RNA) VCaP cells
mixed with 200 LNCaP cells (Figure 2C).
As RT-PCR is limited to detecting the fusion
transcript in single cells, we applied FISH to analyze the
genomic truncation of ERG (which is the result
of TMPRSS2:ERG fusion) in individual cells. Isolated CTC
from 10 of the 15 blood samples were available for this
type of analysis, and we found ERG truncation in 6 of
them, including the sample accompanied by a
TMPRSS2:ERG fusion positive primary tumor (Table 2, Figure 3).
Although the frequency of TMPRSS2:ERG fusion was
higher than that detected in our primary samples, it was
not statistically significant (P = 0.319)
4 Discussion
There are currently no reliable markers for
predicting the behavior of prostate cancer diagnosed at an early
stage. Subsequently, there is a dilemma as to how to
treat localized tumors, which are increasingly being
detected by PSA screening of tumors. The high frequency
of TMPRSS2:ERG fusion in prostate cancer and the
detection of the fusion transcript in early stage cancers and
even pre-cancerous lesions [27, 31] has promted
investigations into the potential of using the fusion product to
predict cancer progression [9_12, 14_17].
In the present study, we detected a high frequency
of the TMPRSS2:ERG fusion gene in primary prostate
cancer biopsies from radical prostatectomy using
RT-PCR, which is comparable to previous studies [5, 14,
27_33]. We also found the co-existence of multiple forms
of fusion variants of TMPRSS2:ERG, which correlates
with several previous studies [14, 27_30]. Most importantly, we detected that
ERG truncation generally resulted from the gene fusion at a high frequency (6/10)
in CTC samples prepared from the peripheral blood,
suggesting that cancer cells with TMPRSS2:ERG
fusion frequently migrate into the blood vessel for long distance
seeding. Our observation of TMPRSS2:ERG fusion gene
positive CTC is consistent with a previous observation
where fusion genes were passed on from the primary
tumors to lymph node metastatic cells [34]. The
frequency of TMPRSS2:ERG fusion was not significantly
higher in the CTC samples when compared to that detected in our primary samples. However, the number of
CTC samples analyzed in the present study is small, and
further investigation of this fusion gene in a larger series
of CTC samples will be required.
CTC analysis can be used to monitor tumor
progression and response to therapies [35].
However, no markers can currently be used to separate cancer from
normal prostate cells. Truncation of ERG or fusion of
TMPRSS2:ERG is a specific marker for cancer cells.
The TMPRSS2:ERG fusion may be used to detect
tumor cells circulating in the blood in a large proportion of
cases, although not all cases of CTC may be identified.
This makes the detection of ERG truncation or
TMPRSS2:ERG fusion in CTC a specific tool for
monitoring tumor metastasis before apparent long distance
metastasis occurs. In our study, we detected ERG
alteration positive cells in two cases of prostate cancers
without detected metastatic tumors. The present study
has mainly established the principle in detecting
TMPRSS2:ERG fusion in CTC using advanced prostate
cancers. Further investigation is required to evaluate its
application in monitoring early stage disease.
Although the TMPRSS2:ERG fusion was detected
at the genomic level, we did not detect the fusion
transcript in any of the CTC isolated from patient blood
samples. RT-PCR is a sensitive method for detecting
fusion gene transcripts in a small amount of cells. The
protocol we used can detect a sample containing
20 TMPRSS2:ERG fusion positive cells from the VCaP cell
line. There are more than 100 prostate epithelial cells in
each of the selected populations from blood
samples determined by immunostaining using
EpCAM. Although we still cannot absolutely exclude the limitation of
technical sensitivity as a reason for the failure to detect the
fusion transcripts in the small number of CTC, it is most
likely that the expression of TMPRSS2:ERG is switched
off/down in the CTC. First, as all the patients are
androgen independent, it is most likely that fusion gene
expression in CTC from these patients is switched-off/down
as a result of androgen ablation therapy [36]. In a
previous report, the expression of TMPRSS2:ERG
was not detectable in androgen independent cancers, including
some metastatic samples, although the genomic fusion
existed in some cases [14]. Second, most of the CTC in
the blood stream fail to proliferate in culture and appear
terminally differentiated, which might also affect fusion
gene expression.
In summary, we have detected a high frequency
of TMPRSS2:ERG fusion not just in the primary tumors
but also in CTC. Although the expression of
TMPRSS2:ERG fusion gene was not detected in CTC, genomic
detection of the fusion gene by FISH in CTC could be
used clinically to monitor the early signs of prostate
cancer metastasis.
Acknowledgment
We thank the Orchid Cancer Appeal and Prostate
Research Campaign UK for funding support. David M.
Prowse is a Research Council UK Academic fellow.
References
1 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor
A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:
10_30.
2 Ulbright TM. Male genital tract. In: Alison MR, editor. The
Cancer Handbook. London: Nature publishing group; 2002:
p665_87.
3 Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH, Ma X,
et al. Prostate androgen-regulated gene: a novel potential target for
androgen-independent prostate cancer therapy. Asian J Androl
2006; 8: 455_62.
4 Yang J, Wu HF, Qian LX, Zhang W, Hua LX, Yu ML,
et al. Increased expressions of vascular endothelial growth factor
(VEGF), VEGF-C and VEGF receptor-3 in prostate cancer
tissue are associated with tumor progression. Asian J Androl
2006; 8: 169_75.
5 Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra
R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS
transcription factor genes in prostate cancer. Science 2005;
310: 644_8.
6 Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D,
Helgeson BE, et al. TMPRSS2:ETV4 gene fusions define a
third molecular subtype of prostate cancer. Cancer Res 2006;
66: 3396_400.
7 Yin JA, Grimwade D. Minimal residual disease evaluation in
acute myeloid leukaemia. Lancet 2002; 360: 160_62.
8 Rowley JD. Chromosome translocations: dangerous liaisons
revisited. Nat Rev Cancer 2001; 1: 245_50.
9 Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular
genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1
gene fusions in 50 cases of prostate cancer. Oncol Rep 2007;
17: 1033_6.
10 Rajput AB, Miller MA, De Luca A, Boyd N, Leung S,
Hurtado-Coll A, et al. Frequency of the TMPRSS2:ERG gene fusion is
increased in moderate to poorly differentiated prostate cancers.
J Clin Pathol 2007; 60: 1238_43.
11 Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH,
et al. Expression of
TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.
Cancer Biol Ther 2007; 6: 40_5.
12 Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT,
et al. Comprehensive assessment of
TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol
2007; 20: 538_44.
13 Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de
Rijn M, et al. A variant
TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular
diagnosis. Mod Pathol 2007; 20: 467_73.
14 Hermans KG, van Marion R, van Dekken H, Jenster G, van
Weerden WM, Trapman J. TMPRSS2:ERG fusion by
translocation or interstitial deletion is highly relevant in
androgen-dependent prostate cancer, but is bypassed in late-stage
androgen receptor-negative prostate cancer. Cancer Res 2006;
66: 10658_63.
15 Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur
SR, et al. TMPRSS2:ERG gene fusion associated with lethal
prostate cancer in a watchful waiting cohort. Oncogene 2007;
26: 4596_9.
16 Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P,
et al. Duplication of the fusion of
TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:
253_63.
17 Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL,
Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an
early molecular event associated with invasion. Am J Surg
Pathol 2007; 31: 882_8.
18 Fleming JA, Stewart JW. A critical and comparative study of
methods of isolating tumor cells from the blood. J Clin Pathol
1967; 20: 145_51.
19 Pelkey TJ, Frierson HF Jr, Bruns DE. Molecular and
immunological detection of circulating tumor cells and
micrometastases from solid tumors. Clin Chem 1996; 42: 1369_81.
20 Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle
GV, Pienta KJ, et al. Global gene expression profiling of
circulating tumor cells. Cancer Res 2005; 65: 4993_7.
21 Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich
D, et al. Detection of HER-2/neu-positive circulating epithelial
cells in prostate cancer patients. Br J Cancer 2004; 90: 443_8.
22 Li X, Wong C, Mysel R, Slobodov G, Metwalli A, Kruska J,
et al. Screening and identification of differentially expressed transcripts
in circulating cells of prostate cancer patients using suppression
subtractive hybridization. Mol Cancer 2005; 4: 30.
23 McIntyre IG, Spreckley K, Clarke RB, Anderson E, Clarke
NW, George NJ. Optimization of the reverse transcriptase
polymerase chain reaction for the detection of circulating
prostate cells. Br J Cancer 2000; 83: 992_7.
24 Llanes L, Ferruelo A, Paez A, Gomez JM, Moreno A,
Berenguer A. The clinical utility of the prostate specific
membrane antigen reverse-transcription/polymerase chain reaction
to detect circulating prostate cells: an analysis in healthy men
and women. BJU Int 2002; 89: 882_5.
25 Llanes L, Paez A, Ferruelo A, Lujan M, Romero I, Berenguer
A. Detecting circulating prostate cells in patients with
clinically localized prostate cancer: clinical implications for
molecular staging. BJU Int 2000; 86: 1023_7.
26 Lu YJ, Birdsall S, Summersgill B, Smedley D, Osin P, Fisher
C, et al. Dual colour fluorescence in situ hybridization to
paraffin-embedded samples to deduce the presence of the
der(X)t(X;18)(p11.2;q11.2) and involvement of either the
SSX1 or SSX2 gene: a diagnostic and prognostic aid for synovial
sarcoma. J Pathol 1999; 187: 490_6.
27 Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS,
et al. Diversity of TMPRSS2-ERG fusion transcripts in the human
prostate. Oncogene 2007; 26: 2667_73.
28 Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI,
et al. TMPRSS2 fusions with oncogenic ETS factors in
prostate cancer involve unbalanced genomic rearrangements and
are associated with HDAC1 and epigenetic reprogramming.
Cancer Res 2006; 66: 10242_6.
29 Wang J, Cai Y, Ren C, Ittmann M. Expression of Variant
TMPRSS2/ERG Fusion Messenger RNAs Is Associated with
Aggressive Prostate Cancer. Cancer Res 2006; 66: 8347_51.
30 Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R,
Panagopoulos I. Confirmation of the high frequency of the
TMPRSS2/ERG fusion gene in prostate cancer. Genes
Chromosomes Cancer 2006; 45: 717_9.
31 Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R,
Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG
overexpression precedes chromosome copy number changes
in prostate carcinomas and paired HGPIN lesions. Neoplasia
2006; 8: 826_32.
32 Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J,
Selvarajah S, Evans AJ, et al.
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that
genomic microdeletion of chromosome 21 is associated with
rearrangement. Neoplasia 2006; 8: 465_9.
33 Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson
BE, et al. Noninvasive detection of TMPRSS2:ERG fusion
transcripts in the urine of men with prostate cancer.
Neoplasia 2006; 8: 885_8.
34 Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera
JM, Setlur S, et al.
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Cancer Res 2006; 66: 8337_41.
35 Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A,
Miller MC, et al. Circulating tumor cells at each follow-up
time point during therapy of metastatic breast cancer patients
predict progression-free and overall survival. Clin Cancer Res
2006; 12: 4218_24.
36 Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD,
et al. Prostate-localized and and rogen-regulated expression of the
membrane-bound serine protease TMPRSS2. Cancer Res 1999;
59: 4180_4.
|